New FDA draft guidance seeks to clarify UDI forms

A new draft guidance from the U.S. Food and Drug Administration (FDA) aim to clarify how Unique Device Identifiers (UDIs) are included on medical devices.

“Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI)” offers some detailed definitions of how the UDI has to be presented in both “both easily readable plain-text” and the form which can be transferred to an electronic health record or a computer system, known as automatic identification and data capture (AIDC).

For the text form, the guidance say the device identifier, production identifiers, and the data delimiters have to be included. The actual text of the UDI can be multiple lines, and “should be displayed below or near the AIDC technology form of the UDI.”

The AIDC instructions are a bit more complex. The draft guidance says while a particular AIDC system isn’t required, it does recommend the electronic form of the UDI come in some kind of scannable format, like a bar code. Since physical space on devices may be limited, the guidance allows for these codes to be broken up, such as a separate bar code for the device identifier and another for the production identifier.

Labelers could also include multiple types of scannable codes on a device.

The draft guidance also says the device identifier information should be listed before the production identifier, with any non-UDI information listed after the UDI.

Comments on the guidance will be accepted until September 24.  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”